{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Garcia-Manzanares M"],"funding":["Instituto de Salud Carlos III","Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III"],"pagination":["593-600"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7423868"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(4)"],"pubmed_abstract":["Transcriptomic signature of XPO1 was highly expressed and inversely related to left ventricular function in ischemic cardiomyopathy patients. We hypothesized that treatment with AAV9-shXPO1 attenuates left ventricular dysfunction and remodeling in a myocardial infarction rat model. We induced myocardial infarction by coronary ligation in Sprague-Dawley rats (n = 10), which received AAV9-shXPO1 (n = 5) or placebo AAV9-scramble (n = 5) treatment. Serial echocardiographic assessment was performed throughout the study. After myocardial infarction, AAV9-shXPO1-treated rats showed partial recovery of left ventricular fractional shortening (16.8 ± 2.8 vs 24.6 ± 4.1%, P < 0.05) and a maintained left ventricular dimension (6.17 ± 0.95 vs 4.70 ± 0.93 mm, P < 0.05), which was not observed in non-trea"],"journal":["Journal of cardiovascular translational research"],"pubmed_title":["XPO1 Gene Therapy Attenuates Cardiac Dysfunction in Rats with Chronic Induced Myocardial Infarction."],"pmcid":["PMC7423868"],"funding_grant_id":["PI17/01232","PI16/01627","CB16/11/00261","PI17/01925"],"pubmed_authors":["Garcia-Manzanares M","Lago F","Rosello-Lleti E","Gonzalez-Juanatey JR","Portoles M","Ortega A","Tarazon E","Gil-Cayuela C","Rivera M","Martinez-Dolz L"],"additional_accession":[]},"is_claimable":false,"name":"XPO1 Gene Therapy Attenuates Cardiac Dysfunction in Rats with Chronic Induced Myocardial Infarction.","description":"Transcriptomic signature of XPO1 was highly expressed and inversely related to left ventricular function in ischemic cardiomyopathy patients. We hypothesized that treatment with AAV9-shXPO1 attenuates left ventricular dysfunction and remodeling in a myocardial infarction rat model. We induced myocardial infarction by coronary ligation in Sprague-Dawley rats (n = 10), which received AAV9-shXPO1 (n = 5) or placebo AAV9-scramble (n = 5) treatment. Serial echocardiographic assessment was performed throughout the study. After myocardial infarction, AAV9-shXPO1-treated rats showed partial recovery of left ventricular fractional shortening (16.8 ± 2.8 vs 24.6 ± 4.1%, P < 0.05) and a maintained left ventricular dimension (6.17 ± 0.95 vs 4.70 ± 0.93 mm, P < 0.05), which was not observed in non-trea","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2025-04-18T17:41:51.528Z","creation":"2025-04-07T05:18:17.737Z"},"accession":"S-EPMC7423868","cross_references":{"pubmed":["31768947"],"doi":["10.1007/s12265-019-09932-y"]}}